Insulet (Insulet) Debt-to-Asset : 0.55 (As of Dec. 2023)

View and export this data going back to 2007. Start your Free Trial

What is Insulet Debt-to-Asset?

Insulet's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $49 Mil. Insulet's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $1,366 Mil. Insulet's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Dec. 2023 was $2,588 Mil. Insulet's debt to asset for the quarter that ended in Dec. 2023 was 0.55.

Insulet Debt-to-Asset Historical Data

The historical data trend for Insulet's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Insulet Debt-to-Asset Chart

Insulet Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Asset

Get a 7-Day Free Trial

0.78

0.57

0.62

0.55

Insulet Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Debt-to-Asset	Get a 7-Day Free Trial															0.62	0.61	0.59	0.58	0.55

Competitive Comparison of Insulet's Debt-to-Asset

For the Medical Devices subindustry, Insulet's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Insulet's Debt-to-Asset Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Insulet's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Insulet's Debt-to-Asset falls into.

Insulet Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Insulet's Debt-to-Asset for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(49.4	+	1366.4)	/	2588.2
	=	0.55

Insulet's Debt-to-Asset for the quarter that ended in Dec. 2023 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(49.4	+	1366.4)	/	2588.2
	=	0.55

Insulet (NAS:PODD) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

Insulet Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Insulet's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Insulet (Insulet) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Insulet Corp (NAS:PODD) » Definitions » Debt-to-Asset

Comparable Companies

Traded in Other Exchanges

PODD:Mexico GOV:Germany GOV:Germany

Address

100 Nagog Park, Acton, MA, USA, 01720

Website

https://www.insulet.com

Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device and that can be operated through a smartphone to control dosage. Since the Omnipod was approved by the U.S. Food and Drug Administration in 2005, approximately 360,000 insulin-dependent diabetics are using it worldwide.

Executives

Luciana Borio	director	C/O EAGLE PHARMACEUTICALS, INC., 50 TICE BLVD., SUITE 315, WOODCLIFF LAKE NJ 07677
Shacey Petrovic	officer: CCO	600 TECHNOLOGY PARK DRIVE, SUITE 200, BILLERICA MA 01821
Prem Singh	officer: SVP, Global Operations	C/O INSULET CORPORATION, 100 NAGOG PARK, ACTON MA 01720
James Hollingshead	director	C/O RESMED INC., 9001 SPECTRUM CENTER BOULEVARD, SAN DIEGO CA 92123
Wayde D. Mcmillan	officer: EVP, CFO	C/O INSULET CORPORATION, 100 NAGOG PARK, ACTON MA 01720
Mark N Field	officer: SVP & Chief Technology Officer	C/O INSULET CORPORATION, 100 NAGOG PARK, ACTON MA 01720
Dan Manea	officer: SVP, Chief HR Officer	C/O INSULET CORPORATION, 100 NAGOG PARK, ACTION MA 01720
Michael R Minogue	director	22 CHERRY HILL DR, C/O ABIOMED INC, DANVERS MA 01923
Laetitia Cousin	officer: SVP, Reg, Quality & Compliance	C/O INSULET CORPORATION, 100 NAGOG PARK, ACTON MA 01720
Charles Alpuche	officer: SVP, Global Manufacturing	C/O INSULET CORPORATION, 600 TECHNOLOGY PARK DRIVE, SUITE 200, BILLERICA MA 01821
Bret Christensen	officer: SVP and CCO	600 TECHNOLOGY PARK DRIVE, SUITE 200, BILLERICA MA 01821
Michael P Spears	officer: SVP, Quality and Regulatory	C/O INSULET CORPORATION, 600 TECHNOLOGY PARK DRIVE, SUITE 200, BILLERICA MA 01821
Elizabeth H Weatherman	director	C/O WARBURG PINCUS LLC, 450 LEXINGTON AVENUE, NEW YORK NY 10017
David A Lemoine	director	C/O THE L S STARRETT COMPANY, 121 CRESCENT STREET, ATHOL MA 01331
Sally Crawford	director	C/O HOLOGIC, INC., BEDFORD MA 01730